How does DSM N's PE Ratio compare to its peers?

DSM N is good value based on its Price-To-Earnings Ratio (1.7x) compared to the peer average (17.3x).

How does DSM N's PE Ratio compare vs other companies in the Global Chemicals Industry?

DSM N is good value based on its Price-To-Earnings Ratio (1.7x) compared to the Global Chemicals industry average (21.8x).

What is DSM N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate DSM N's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of DSM N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DSM N (MX$2194.2) is trading below our estimate of [[fair value]] (MX$9559.56)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DSM N Stock Overview

Provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. More details

DSM N fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	1/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 77% below our estimate of its fair value

Earnings are forecast to grow 20.53% per year

Analysts in good agreement that stock price will rise by 30.9%

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Profit margins (5.4%) are lower than last year (11.3%)

My Notes

Capture your thoughts, links and company narrative

DSM-Firmenich AG Competitors

Grupo México. de

BMV:GMEXICO B

Mex$809.0b

CEMEX. de

BMV:CEMEX CPO

Mex$162.2b

Orbia Advance Corporation. de

BMV:ORBIA *

Mex$31.8b

Givaudan

SWX:GIVN

CHF 37.5b

Price History & Performance

Summary of share price highs, lows and changes for DSM-Firmenich
Historical stock prices
Current Share Price	€2,194.20
52 Week High	€2,891.06
52 Week Low	€2,194.20
Beta	0.72
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	-25.43%
3 Year Change	n/a
5 Year Change	11.50%
Change since IPO	11.50%

Recent updates

Shareholder Returns

	DSM N	MX Chemicals	MX Market
7D	0%	-4.0%	-1.1%
1Y	-25.4%	-25.9%	-12.5%

Return vs Industry: DSM N underperformed the MX Chemicals industry which returned -18.2% over the past year.

Return vs Market: DSM N underperformed the MX Market which returned -3.1% over the past year.

Price Volatility

Is DSM N's price volatile compared to industry and market?
DSM N volatility
DSM N Average Weekly Movement	n/a
Chemicals Industry Average Movement	4.2%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.0%
10% least volatile stocks in MX Market	2.8%

Stable Share Price: DSM N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine DSM N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1902	19,973	Dimitri de Vreeze	www.dsm-firmenich.com

DSM-Firmenich AG, a science-based company, engages in health and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants.

DSM-Firmenich AG Fundamentals Summary

How do DSM-Firmenich's earnings and revenue compare to its market cap?
DSM N fundamental statistics
Market cap	Mex$14.40b
Earnings (TTM)	Mex$8.56b
Revenue (TTM)	Mex$158.15b

1.7x

P/E Ratio

0.1x

P/S Ratio

Is DSM N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DSM N income statement (TTM)
Revenue	€8.39b
Cost of Revenue	€5.70b
Gross Profit	€2.69b
Other Expenses	€2.24b
Earnings	€454.00m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

Aug 02, 2023

Earnings per share (EPS)	67.80
Gross Margin	32.06%
Net Profit Margin	5.41%
Debt/Equity Ratio	26.6%

How did DSM N perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

96%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/05/31 13:42
End of Day Share Price	2023/05/11 00:00
Earnings	2022/12/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DSM-Firmenich AG is covered by 61 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Mutlu Gundogan	ABN AMRO Bank N.V.
Martin Schnee	AlphaValue
Volker Bosse	Baader Helvea Equity Research